Stock Analysis of Pulmatrix Inc (PULM) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code PULM
Close 1.87
Change 0.0300 / 1.63 %
Volume 5410.00
Vol Change 851.00 / 18.67 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Pulmatrix Inc
PE (TTM)

-386.34

Very Poor
Price / Book

159.21

Very Poor
Price / Sales

292.56

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

6829.76 K

Enterprise Value

-11914.24 K

ROA (TTM)

-26.24

Very Poor
ROE (TTM)

-41.21

Very Poor
Net Margin (TTM)

-75.73

Very Poor
Revenue

111973 %

6804.00 K
Net Profit

86192.21 %

-16254.00 K
Debt to Equity

0.0238

Excellent
Altman Z Score

-12.36

Very Poor
Quick Ratio

0

Poor
Cash Ratio

4.90

Very Good


Highs/Lows of Pulmatrix Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.8883 0.969 % 0.513 % 1.99991.7231-May-2429-May-24
Two Week1.91 2.09 % 0.486 % 2.091.7221-May-2429-May-24
One Month1.9001 1.58 % 4.80 % 2.091.7221-May-2429-May-24
Three Month1.99 6.03 % 3.56 % 2.191.5516-Apr-2419-Mar-24
Six Months2.06 9.22 % 15.54 % 2.341.5503-Jan-2419-Mar-24
One year2.7297 31.49 % 26.26 % 2.881.5520-Jun-2319-Mar-24
Two year5.4027 65.39 % 27.72 % 4.491.5513-Jan-2319-Mar-24
Five year20.4 90.83 % 91.77 % 6.11.5525-Aug-2219-Mar-24
Ten year3175.0 99.94 % 174.36 % 3425.01.5518-Jun-1419-Mar-24


Technical View of Pulmatrix Inc
RSI

47.43

Neutral
MACD

-0.0107

Mild Bearish
ADX

14.96

Mild Bullish
Super Trend

1.70

Mild Bullish
Williams %R

-59.46

Neutral
CCI

13.74

Neutral


EMA 5

1.87

Mild Bearish
EMA 15

1.89

Mild Bearish
EMA 50

1.90

Strong Bearish
EMA 100

1.91

Whipsaw
SMA 100

1.87

Whipsaw
SMA 200

1.96

Whipsaw
SMA 5 / 20

1.86 / 1.88

Bearish
SMA 15 / 50

1.88 / 1.90

Bearish
SMA 50 / 200

1.90 / 1.96

Mild Bearish




Charts of Pulmatrix Inc


Returns of Pulmatrix Inc with Peers
Period / StockPULMHEPAKZIATBIO
1 Week-0.969%12.51%-6.91%18.26%
1 Mth-1.58%-7.69%-22.34%-37.21%
3 Mth-6.03%-57.58%1.92%-59.42%
6mth-9.22%-60.87%-53.63%-45.86%
1 Year-31.49%-86.88%-78.15%-85.83%
2 Year-65.39%-91.92%-95.51%-94.30%
5 Years-90.83%-99.16%-91.82%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Pulmatrix Inc with Peers
Ratio / StockPULMHEPAKZIATBIO
PE-386.34-0.115-2.68-0.150
P/B159.210.2513.480.179
ROA-26.24-147.92-57.64-51.13
ROE-41.21-218.45-149.45-30903.01
Debt To Equity0.02380.01590.1490.240
Revenue6804.00 K
111973 % 		0
% 		555.00
2120.00 % 		30001.00 K
9.35 %
Net Income-16254.00 K
86192.21 % 		-44677.89 K
5.87 % 		-20465.18 K
16.97 % 		-38169.00 K
21.25 %


Technicals of Pulmatrix Inc with Peers
Technical / StockPULMHEPAKZIATBIO-
ADX14.9620.1131.9314.97
CMF-0.224-0.2270.0356-0.0097
MFI63.8849.7437.4244.60
RSI47.4343.1741.3539.21
MACD Abv SignalFalseTrueFalseTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Pulmatrix Inc

Address : 99 Hayden Avenue, Lexington, MA, United States, 02421
Tel : 781 357 2333
URL : https://www.pulmatrix.com
Code : PULM, ISIN : US74584P3010, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 21_Mar_2014
Employee Count : 22

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)